v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Beginning balance at Dec. 31, 2024 $ 76 $ 421,528 $ (378,393) $ 43,211
Beginning balance (in shares) at Dec. 31, 2024 [1] 75,850,275      
Issuance of common stock under the Sales Agreement, net $ 3 6,809   6,812
Issuance of common stock under the Sales Agreement, net (in shares) [1] 2,775,215      
Share-based compensation related to stock options   599   599
Share-based compensation related to restricted stock awards   368   368
Exercise of warrants and options $ 1 2,367   2,368
Exercise of warrants and options (in shares) [1] 1,106,625      
Net income (loss) for the period     (3,455) (3,455)
Ending balance at Jun. 30, 2025 $ 80 431,671 (381,848) 49,903
Ending balance (in shares) at Jun. 30, 2025 [1] 79,732,115      
Beginning balance at Mar. 31, 2025 $ 78 427,142 (382,012) 45,208
Beginning balance (in shares) at Mar. 31, 2025 [1] 78,133,829      
Issuance of common stock under the Sales Agreement, net $ 2 3,949   3,951
Issuance of common stock under the Sales Agreement, net (in shares) [1] 1,450,036      
Share-based compensation related to stock options   263   263
Share-based compensation related to restricted stock awards   164   164
Exercise of warrants and options   153   153
Exercise of warrants and options (in shares) [1] 148,250      
Net income (loss) for the period     164 164
Ending balance at Jun. 30, 2025 $ 80 431,671 (381,848) 49,903
Ending balance (in shares) at Jun. 30, 2025 [1] 79,732,115      
Beginning balance at Dec. 31, 2025 $ 80 433,147 (384,997) 48,230
Beginning balance (in shares) at Dec. 31, 2025 [1] 80,425,981      
Share-based compensation related to stock options   632   632
Share-based compensation related to restricted stock awards   298   298
Exercise of warrants and options $ 1 149   150
Exercise of warrants and options (in shares) [1] 145,661      
Net income (loss) for the period     22,094 22,094
Ending balance at Jun. 30, 2026 $ 81 434,226 (362,903) 71,404
Ending balance (in shares) at Jun. 30, 2026 [1] 80,571,642      
Beginning balance at Mar. 31, 2026 $ 81 433,828 (366,680) 67,229
Beginning balance (in shares) at Mar. 31, 2026 [1] 80,571,642      
Share-based compensation related to stock options   270   270
Share-based compensation related to restricted stock awards   128   128
Net income (loss) for the period     3,777 3,777
Ending balance at Jun. 30, 2026 $ 81 $ 434,226 $ (362,903) $ 71,404
Ending balance (in shares) at Jun. 30, 2026 [1] 80,571,642      
[1] Common stock, $0.001 par value; Authorized – as of June 30, 2026 and December 31, 2025 – 185,000,000 shares.